检索结果-南通市图书馆

BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months casecontrol study

引用

World Journal of Clinical Pediatrics 2024年第1期13卷 52-61页

作者： Elvira Kalashnikova Eugenia Isupova Ekaterina Gaidar Lyubov Sorokina Maria Kaneva Vera Masalova Margarita Dubko tatiana kornishina Natalia Lubimova Ekaterina Kuchinskaya Irina Chikova Rinat Raupov Olga Kalashnikova Mikhail Kostik Hospital Pediatry Department Saint-Petersburg State Pediatric Medical UniversitySaint-Petersburg 194100Russia Research Laboratory of Autoimmune and Autoinflammatory Diseases Almazov National Medical Research CentreSaint Petersburg 197341Russia Department of Rheumatology Turner National Medical Research Center forСhildren’s Orthopedics and Trauma SurgerySaint-Petetrsburg 197136Russia

BACKGROUND Systemic lupus erythematosus(SLE)is the most frequent and serious systemic connective tissue *** there is no clear guidance on its treatment in *** are a lot of negative effects of standard-of-care treatment(SOCT),including steroid ***(RTX)is the biological B-lymphocyte-depleting agent suggested as a basic therapy in pediatric *** To compare the benefits of RTX above *** The data from case histories of 79 children from the Saint-Petersburg State Pediatric Medical University from 2012 to 2022 years,were *** diagnosis of SLE was established with SLICC *** compared the outcomes of treatment of SLE in children treated with and without *** data,doses of glucocorticosteroids,disease activity measured with SELENA-SLEDAI,RESULTS Patients,treated with RTX initially had a higher degree of disease activity with prevalence of central nervous system and kidney involvement,compared to patients with *** year later the disease characteristics became similar between groups with a more marked reduction of disease activity(SELENA-SLEDAI activity index)in the children who received RTX[-19 points(17;23)since baseline]compared to children with SOCT[-10(5;15.5)points since baseline,P=0.001],the number of patients with active lupus nephritis,and daily *** RTX therapy,infectious diseases had three patients;one patient developed a *** RTX can be considered as the option in the treatment of severe forms of SLE,due to its ability to arrest disease activity compared to SOCT.

关键词： Systemic lupus erythematosus Children Rituximab Anti-B-cell therapy Glucocorticosteroids

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：